Diagnostic Imaging's Weekly Scan: March 26-April 1

The combination of Philips’ MR 7700 multi-nuclei scanner with the FDA-approved Xenoview hyperpolarized Xenon magnetic resonance imaging (MRI) contrast agent may facilitate earlier diagnosis and intervention for patients with obstructive lung diseases.

An interview with two experts to discuss newly released guidance for using standardized MRI protocols for patients with this condition.

The artificial intelligence (AI)-powered Ezra Flash reportedly enhances magnetic resonance imaging (MRI) and enables significant reductions in scan times and costs for full-body MRI.

Drs. Charles Liu and Jonathan Russin discuss the benefits and potential of fPACT, the alternative to functional MRI.

Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.

Review the case study and test your knowledge to make the correct diagnosis.